Drug
Ruxolitinib
Ruxolitinib: highest development phase Post-Market, developed by Incyte, Novartis, United Therapeutics. 18 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Incyte, Novartis, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ruxolitinib NCT06462469 | Post-Market | Steroid-refractory Acute Graft Versus Host Disease |
| Ruxolitinib NCT03112603 | Phase 3 | Graft-versus-host Disease (GVHD) |
| Ruxolitinib Cream NCT06958211 | Phase 3 | Hidradenitis Suppurativa |
| Ruxolitinib cream NCT05233410 | Phase 3 | Chronic Hand Eczema (CHE) |
| Ruxolitinib NCT02117479 | Phase 3 | Pancreatic Cancer |
| Ruxolitinib Cream NCT05764161 | Phase 3 | Prurigo Nodularis |
| Ruxolitinib NCT04116502 | Phase 3 | Polycythemia Vera |
| Ruxolitinib NCT02119650 | Phase 2 | NSCLC (Non-small Cell Lung Carcinoma) |
| Ruxolitinib NCT07228624 | Phase 2 | Myelodysplastic/Myeloproliferative Neoplasm |
| Ruxolitinib NCT06345495 | Phase 2 | Splenomegaly |
| Ruxolitinib NCT06991101 | Phase 2 | Glioblastoma |
| Ruxolitinib NCT01445769 | Phase 2 | Primary Myelofibrosis |
| Ruxolitinib NCT03722407 | Phase 2 | Chronic Myelomonocytic Leukemia |
| Ruxolitinib NCT02119676 | Phase 2 | CRC (Colorectal Cancer) |
| Ruxolitinib cream NCT03099304 | Phase 2 | Vitiligo |
| Ruxolitinib IR NCT06555081 | Phase 1 | Healthy Participants |
| Ruxolitinib NCT01317875 | Phase 1 | Myelofibrosis |
| Ruxolitinib NCT07424222 | Phase 1 | Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) |
Latest
Follow Ruxolitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.